Wednesday, 15 August 2012

Topcare Sleep Aid





Dosage Form: tablet
Topco Sleep Aid Tablets Drug Facts

Active ingredient (in each tablet)


Doxylamine succinate 25 mg



Purpose


Nighttime sleep-aid



Uses


  • helps to reduce difficulty in falling asleep


Warnings


Ask a doctor before use if you have


  • a breathing problem such as asthma, emphysema or chronic bronchitis

  • glaucoma

  • trouble urinating due to an enlarged prostate gland


Do not give


to children under 12 years of age



Ask a doctor or pharmacist before use if you are


taking any other drugs



When using this product


  • avoid alcoholic beverages

  • take only at bedtime


Stop use and ask a doctor if


  • sleeplessness persists continuously for more than two weeks. Insomnia may be a symptom of serious underlying medical illness.


If pregnant or breast-feeding,


ask a health professional before use.



Keep out of reach of children.


In case of overdose, get medical help or contact a Poison Control Center right away.



Directions


  • adults and children 12 years of age and over: take one tablet 30 minutes before going to bed; take once daily or as directed by a doctor

  • children under 12 years of age: do not use


Other information


  • store at 68°-77°F (20°-25°C)

  • retain in carton until time of use

  • see carton end panel for lot number and expiration date


Inactive ingredients


dibasic calcium phosphate, FD&C blue no. 1 aluminum lake, magnesium stearate, microcrystalline cellulose, sodium starch glycolate



Questions or comments?


1-888-423-0139



Principal Display Panel


Fall Asleep Fast!


Safe


Sleep Aid Tablets


Doxylamine Succinate Tablets, 25 mg


Nighttime Sleep-Aid


Proven Effective


Just One Tablet Per Dose


Actual Size


Compare to Unisom® SleepTabs® active ingredient


Sleep Aid Tablets Carton










Topcare Sleep Aid 
doxylamine succinate  tablet










Product Information
Product TypeHUMAN OTC DRUGNDC Product Code (Source)36800-441
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
DOXYLAMINE SUCCINATE (DOXYLAMINE)DOXYLAMINE SUCCINATE25 mg





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
ColorBLUEScoreno score
ShapeOVALSize10mm
FlavorImprint CodeL441
Contains      














Packaging
#NDCPackage DescriptionMultilevel Packaging
136800-441-642 BLISTER PACK In 1 CARTONcontains a BLISTER PACK
116 TABLET In 1 BLISTER PACKThis package is contained within the CARTON (36800-441-64)










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
ANDAANDA04016701/29/1997


Labeler - Topco Associates LLC (006935977)
Revised: 06/2009Topco Associates LLC




More Topcare Sleep Aid resources


  • Topcare Sleep Aid Side Effects (in more detail)
  • Topcare Sleep Aid Use in Pregnancy & Breastfeeding
  • Drug Images
  • Topcare Sleep Aid Drug Interactions
  • Topcare Sleep Aid Support Group
  • 8 Reviews for Topcare Sleep Aid - Add your own review/rating


Compare Topcare Sleep Aid with other medications


  • Allergies
  • Conjunctivitis, Allergic
  • Hay Fever
  • Insomnia
  • Nasal Congestion
  • Rhinorrhea
  • Upper Respiratory Tract Infection

Saturday, 11 August 2012

Sentry HC Dermasphere Medicated Shampoo





Dosage Form: FOR ANIMAL USE ONLY
Medicated Shampoo For Dogs

Indications and Usage for Sentry HC Dermasphere Medicated Shampoo


Sentry HC Dermasphere Medicated Shampoo For Dogs is an antiseborrheic shampoo that aids in the removal of scales, crust, and excessive skin oil associated with seborrhea and other non-specific skin conditions.  Combines the proven benefits of oatmeal, sulfur and salicylic acid.  Contains Dermaspheres, a micro encapsulation technology that holds key ingredients in miscroscopic spheres and improves th effectiveness of the shampoo.


SIGNS:  Recommended for dogs with oily skin and coat.

  • Specially formulated for seborrhea and other skin conditions


  • Medicated Dermaspheres attach to skin and coat and release over time


  • Aids in the removal of scales, crust and excessive skin oil


DIRECTIONS FOR USE


Shake well before use.  Wet the hair coat with warm water.  Apply a thin line of shampoo from the base of the neck to the base of the tail.  Massage the shampoo into wet hair coat.  Rinse and repeat.  May be used two to three times a week.  Discontinue use and consult a veterinarian if undue skin irritation develops or increases, or if the condition persists or recurs, as symptoms may be indicative of an underlying serious condition.

CAUTION


For Animal Use Only.  FOR EXTERNAL USE ONLY.  Avoid contact with eyes or mucous membranes.  In case of contact, flush eyes with water and seek medical attention if irritation persists.

KEEP OUT OF REACH OF CHILDREN




Warnings


Wash hands after use.  In case if accidental ingestion, seek professional assistance or contact a Poison Control Center immediately.

ACTIVE INGREDIENTS


Salicylic Acid 2%, Solubilized Sulfur 2%.

OTHER INGREDIENTS


Water, Sodium Lauryl Sulfate, Lauramide DEA, Glycerin, Colloidal Oatmeal, Dermaspheres, Magnesium Aluminum Silicate, Sodium Hydroxide, Fragrance, Hydroxypropyl Cellulosa, FD and C Blue #1.  May also contain sodium chloride and/or sodium hydroxide.

How is Sentry HC Dermasphere Medicated Shampoo Supplied


Net 12 fl oz (354 mL)

PACKAGE LABEL.PRINCIPAL DISPLAY PANEL


Distributed by:  Sergeant's Pet Care Products, Inc., Omaha NE 68130


Made in USA


PATENTED DERMASPHERE TECHNOLOGY


Patent #6,277,404









Sentry HC Dermasphere Medicated Shampoo FOR DOGS 
salicylic acid, solubilized sulfur  lotion/shampoo










Product Information
Product TypeOTC ANIMAL DRUGNDC Product Code (Source)21091-074
Route of AdministrationTOPICALDEA Schedule    











Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
SALICYLIC ACID (SALICYLIC ACID)SALICYLIC ACID7.08 mL  in 354 mL
SULFUR (SULFUR)SULFUR7.08 mL  in 354 mL





Inactive Ingredients
Ingredient NameStrength
No Inactive Ingredients Found


















Product Characteristics
Colorblue (Aqua Blue)Score    
ShapeSize
FlavorImprint Code
Contains      










Packaging
#NDCPackage DescriptionMultilevel Packaging
121091-074-12354 mL In 1 BOTTLE, PUMPNone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
unapproved drug other11/19/2008


Labeler - Sergeant's Pet Care Products, Inc. (876995171)
Revised: 04/2010Sergeant's Pet Care Products, Inc.



Tuesday, 7 August 2012

Medised for Children





1. Name Of The Medicinal Product



Medised For Children


2. Qualitative And Quantitative Composition



Paracetamol 120mg/5ml



Diphenhydramine HCl 12.5mg/5ml



3. Pharmaceutical Form



Oral solution.



Clear to pale pink liquid.



4. Clinical Particulars



4.1 Therapeutic Indications



For the treatment of mild to moderate pain including teething pain, headache, sore throat, aches and pains.



Symptomatic relief of influenza and feverish colds and the associated symptoms of runny nose and sneezing.



4.2 Posology And Method Of Administration



Route of Administration: Oral.



Recommended Doses and Dosage Schedules:



6 years to under 12 years: 10ml-20ml (2-4 teaspoonful) 3 times daily.



Medised is contraindicated in children under 6 years of age (see section 4.3)



Parents or carers should seek medical attention if the child's condition deteriorates during treatment.



4.3 Contraindications



Do not take if you are hypersensitive to paracetamol, and/or any other constituents.



Large doses of antihistamines may precipitate fits in epileptics.



Do not take if you are currently taking monoamine inhibitors (MAOIs) or within 14 days of stopping treatment with MAOIs.



Not to be used in children under the age of 6 years.



4.4 Special Warnings And Precautions For Use



Do not exceed the stated dose. Immediate medical advice should be sought in the event of an overdose, even if you feel well because of the risk of delayed, serious liver damage.



Do not take with any other paracetamol-containing products, or cough and cold medicines.



Dose should not be repeated more frequently than 4 hour intervals.



Not more than 4 doses should be taken in 24 hours.



Dosage should not be continued for more than three days without consulting a doctor.



This product should be administered with caution to patients with known renal or hepatic impairment, prostatic hypertrophy, urinary retention, or susceptibility to angle-closure glaucoma. The hazards of overdose are greater in those with alcoholic liver disease.



The product may cause drowsiness. This product should not be used to sedate a child.



Keep out of the reach of children.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



The speed of absorption of paracetamol may be increased by metoclopramide or domperidone and absorption reduced by cholestyramine.



The anticoagulant effect of warfarin and other coumarins may be enhanced by prolonged regular daily use of paracetamol with increased risk of bleeding.



May enhance the sedative effects of CNS depressants including barbiturates, hypnotics, opioid analgesics, anxiolytic sedatives, antipsychotics and alcohol.



May have an additive muscarinic actions with other drugs, such as atropine and some antidepressants.



Not to be used in patients taking MAOIs or within 14 days of stopping treatment as there is a risk of serotonin syndrome.



4.6 Pregnancy And Lactation



Safety in pregnancy has not been established.



Epidemiological studies in human pregnancy have shown no effects due to paracetamol used in the recommended dosage, but patients should follow the advice of their doctor regarding its use. Paracetamol is excreted in breast milk, but not a clinically significant amount.



Available published data does not contraindicate breast-feeding.



4.7 Effects On Ability To Drive And Use Machines



May cause drowsiness. If affected do not drive or operate machinery.



4.8 Undesirable Effects



Common side effects



CNS effects: Drowsiness (usually diminishes within a few days), paradoxical stimulation, headache, psychomotor impairment.



Antimuscarinic effects: Urinary retention, dry mouth, blurred vision, gastrointestinal disturbances, thickened respiratory tract secretions



Rare side effects:



Hypotenstion, extrapyramidal effects, dizziness, confusion, depression, sleep disturbances, tremor, convulsions, palpitation, arrhythmia, hypersensitivity reactions (including skin rash), blood disorders and liver dysfunction.



There have been a few reports of blood dyscrasias including thrombocytopenia and agranulocytosis but these were not necessarily causally related to paracetamol.



4.9 Overdose



The features of overdose are: sedation, pallor, nausea, vomiting, diarrhoea, anorexia, and abdominal pain; liver damage may become apparent within 12 to 48 hours. In some children overdose may cause cerebral stimulation resulting in convulsions and hyperpyrexia.



Abnormalities of glucose metabolism and metabolic acidosis may occur. In severe poisoning, hepatic failure may progress to encephalopathy, coma and death. Acute renal failure with acute tubular necrosis may develop even in the absence of severe liver damage. Cardiac arrhythmias and pancreatitis have been reported.



Liver damage is likely in adults who have taken 10g or more of paracetamol. It is considered that excess quantities of a toxic metabolite (usually adequately detoxified by glutathione when normal doses of paracetamol are ingested), become irreversibly bound to liver tissue.



Immediate treatment is essential in the management of paracetamol overdose. Despite a lack of significant early symptoms, patients should be referred to hospital urgently for immediate medical attention and any patient who has ingested around 7.5g or more of paracetamol in the preceding four hours should undergo gastric lavage. Administration of oral methionine or intravenous N-acetylcysteine which may have a beneficial effect up to at least 48 hours after the overdose, may be required. General supportive measures must be available.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Paracetamol is an antipyretic and analgesic. Diphenhydramine HCl is an antihistamine with anti-cholinergic, anti-emetic, anti-allergic and sedative effects.



5.2 Pharmacokinetic Properties



Paracetamol and diphenhydramine HCl are both readily absorbed from the gastrointestinal tract. Both are widely distributed throughout the body. Both are metabolised in the liver and excreted in the urine. As Medised Infant is a solution, absorption of actives is rapid following oral ingestion.



5.3 Preclinical Safety Data



Paracetamol and diphenhydramine HCl are well established drug substances whose preclinical profiles have been investigated and are thoroughly established.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Macrogol 4000



Glycerol



Propylene Glycol



Sorbitol Solution (non crystallising) 70%



Lycasin 80/55 (Maltitol Solution)



Sodium Cyclamate



Sodium Saccharin



Nipasept (Methylhydroxybenzoate, Ethylhydroxybenzoate and Parahydroxybenzoate)



Strawberry Flavour 513805E



Sugar Module 555049E



Water, purified



6.2 Incompatibilities



Not applicable.



6.3 Shelf Life



36 months.



6.4 Special Precautions For Storage



Do not store above 25°C.



Do not refrigerate.



Keep container in outer carton.



6.5 Nature And Contents Of Container



Amber type III glass bottle and plastic clic loc cap with pulp stearan wadding. 20ml, 30ml, 70ml, 100ml, 140ml and 200ml.



All pack sizes except the 20ml have a 5ml plastic spoon.



6.6 Special Precautions For Disposal And Other Handling



None.



7. Marketing Authorisation Holder



SSL International Plc



Venus



1 Old Park Lane



Trafford Park



Manchester



M41 7HA



UK



8. Marketing Authorisation Number(S)



PL 17905/0090



9. Date Of First Authorisation/Renewal Of The Authorisation



13/09/99



10. Date Of Revision Of The Text



September 2009




Sunday, 5 August 2012

G-Vent


Generic Name: guaifenesin and phenylpropanolamine (gwye FEN e sin/fen ill proe pa NOLE a meen)

Brand Names: Ami-Tex LA, Banex-LA, Coldloc-LA, Dayquil Sinus Pressure and Congestion, Despec, Entex LA, Exgest LA, G-Vent, Guaifenex PPA 75, Guaivent, Guiatex LA, Naldecon-EX Pediatric, Nasahist LA, Phentex-LA, Phenylfenesin LA, Poly-Vent, Profen LA, Stamoist LA, Triaminic Expectorant, Vanex-LA


What is G-Vent (guaifenesin and phenylpropanolamine)?

Guaifenesin is an expectorant. It is used to break up congestion and mucous to make breathing easier. Guaifenesin thins mucous, increases lubrication of the respiratory tract (lungs, nose and throat), and increases the removal of mucous.


Phenylpropanolamine is a decongestant. It constricts (shrinks) blood vessels (veins and arteries), which reduces swelling of mucous membranes in areas such as the nose and sinuses.


Guaifenesin and phenylpropanolamine is used to treat the symptoms of the common cold and of infections of the sinuses, lungs, and throat.


Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.


Guaifenesin and phenylpropanolamine may also be used for purposes other than those listed in this medication guide.


What is the most important information I should know about G-Vent (guaifenesin and phenylpropanolamine)?


Phenylpropanolamine, an ingredient in this product, has been associated with an increased risk of hemorrhagic stroke (bleeding into the brain or into tissue surrounding the brain) in women. Men may also be at risk. Although the risk of hemorrhagic stroke is low, the U.S. Food and Drug Administration (FDA) recommends that consumers not use any products that contain phenylpropanolamine.


Drink plenty of extra fluids while taking this medication. Do not crush or chew the tablets. Swallow them whole or break them in half where they are scored to make them easier to swallow if needed.

Who should not take G-Vent (guaifenesin and phenylpropanolamine)?


Do not take guaifenesin and phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Before taking this medication, tell your doctor if you have



  • high blood pressure or any other type of heart disease,




  • diabetes,




  • a peripheral vascular disorder (poor circulation),




  • glaucoma or increased pressure in the eyes,




  • an overactive thyroid, or




  • difficulty urinating or an enlarged prostate.



You may not be able to take guaifenesin and phenylpropanolamine, or you may require a dosage adjustment or special monitoring during treatment if you have any of the conditions listed above.


Guaifenesin and phenylpropanolamine is in the FDA pregnancy category C. This means that it is not known whether guaifenesin and phenylpropanolamine will harm an unborn baby. Do not take this medication without first talking to your doctor if you are pregnant. This medication passes into breast milk and may harm a nursing baby. Do not take this medication without first talking to your doctor if you are breast-feeding a baby. If you are over 65 years of age, you may be more likely to experience side effects from guaifenesin and phenylpropanolamine. You may require a lower dose of this medication. Guaifenesin and phenylpropanolamine has not been approved for use by children younger than 6 years of age.

How should I take G-Vent (guaifenesin and phenylpropanolamine)?


Take guaifenesin and phenylpropanolamine exactly as directed by your doctor. If you do not understand these directions, ask your pharmacist, nurse, or doctor to explain them to you.


Take each dose with a full glass of water. Increasing fluid intake during the day may help relieve congestion. Take guaifenesin and phenylpropanolamine with food if it causes stomach upset. Do not crush or chew the tablets. Swallow them whole or break them in half where they are scored to make them easier to swallow if needed. Store guaifenesin and phenylpropanolamine at room temperature away from moisture and heat.

What happens if I miss a dose?


Take the missed dose as soon as you remember. However, if it is almost time for the next dose, skip the missed dose and take only the next regularly scheduled dose. Do not take a double dose of this medication.


What happens if I overdose?


Seek emergency medical attention.

Symptoms of a guaifenesin and phenylpropanolamine overdose include vomiting, high blood pressure (headache, redness of face, blurred vision), an irregular heartbeat, and numbness of the fingers or toes.


What should I avoid while taking G-Vent (guaifenesin and phenylpropanolamine)?


Use caution when driving, operating machinery, or performing other hazardous activities. Guaifenesin and phenylpropanolamine may cause dizziness. If you experience dizziness, avoid these activities.

G-Vent (guaifenesin and phenylpropanolamine) side effects


No serious side effects from guaifenesin and phenylpropanolamine are expected. Seek emergency medical attention if you experience an allergic reaction (difficulty breathing; closing of your throat; swelling of your lips, tongue, or face; or hives).

Other, less serious side effects may be more likely to occur. Continue to take guaifenesin and phenylpropanolamine and talk to your doctor if you experience



  • dizziness or headache;




  • nervousness, restlessness, or insomnia;




  • nausea or stomach upset; or




  • difficulty urinating.



Side effects other than those listed here may also occur. Talk to your doctor about any side effect that seems unusual or that is especially bothersome.


What other drugs will affect G-Vent (guaifenesin and phenylpropanolamine)?


Do not take guaifenesin and phenylpropanolamine if you have taken a monoamine oxidase inhibitor (MAOI) such as isocarboxazid (Marplan), phenelzine (Nardil), or tranylcypromine (Parnate) in the last 14 days. A dangerous drug interaction could occur, leading to serious side effects.

Heart medications such as methyldopa (Aldomet), reserpine (Serpalan, Serpasil), and guanethidine (Ismelin) may have decreased effects. Talk to your doctor before taking guaifenesin and phenylpropanolamine if you are taking any of these medications.


Do not take other over-the-counter cough, cold, allergy, diet, or sleep aids while taking guaifenesin and phenylpropanolamine without first talking to your doctor or pharmacist. Other medications may also contain guaifenesin, phenylpropanolamine, or other similar drugs. You may accidentally take too much of these medicines.


Drugs other than those listed here may also interact with guaifenesin and phenylpropanolamine. Talk to your doctor and pharmacist before taking any prescription or over-the-counter medicines.



More G-Vent resources


  • G-Vent Side Effects (in more detail)
  • G-Vent Use in Pregnancy & Breastfeeding
  • G-Vent Drug Interactions
  • G-Vent Support Group
  • 0 Reviews for G-Vent - Add your own review/rating


Compare G-Vent with other medications


  • Cough and Nasal Congestion


Where can I get more information?


  • Your pharmacist has additional information about guaifenesin and phenylpropanolamine written for health professionals that you may read.

What does my medication look like?


Guaifenesin and phenylpropanolamine is available with a prescription under several brand names. Ask your pharmacist any questions you have about this medication, especially if it is new to you.



  • Entex LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--orange, scored tablets




  • Exgest LA, 400 mg of guaifenesin and 75 mg of phenylpropanolamine--white, oval-shaped, scored, long-acting tablets with blue speckles




  • Dura-Vent, 600 mg of guaifenesin and 75 mg of phenylpropanolamine--white, scored tablets



See also: G-Vent side effects (in more detail)


Uveitis, Posterior Medications


Drugs associated with Uveitis, Posterior

The following drugs and medications are in some way related to, or used in the treatment of Uveitis, Posterior. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

See sub-topics

Topics under Uveitis, Posterior

  • Infectious Posterior Uveitis (0 drugs)

Learn more about Uveitis, Posterior





Drug List:

Thursday, 2 August 2012

Actidose





Dosage Form: suspension
Actidose® WITH SORBITOL

Actidose®-AQUA

ACTIVATED CHARCOAL SUSPENSION



Actidose Description


Actidose® with Sorbitol: Actidose® with Sorbitol, ready-to-use activated charcoal suspension with sorbitol, contains 25 gm or 50 gm of activated charcoal, and 48 gm or 96 gm of sorbitol, respectively, in an aqueous suspension with a unique preservative system. Each milliliter contains 208 mg (0.208 gm) of activated charcoal and 400 mg (0.400 gm) of sorbitol. Sorbitol reduces the gritty sensation associated with activated charcoal, imparts a sweet taste which enhances patient compliance, and usually produces a cathartic effect.


Actidose®-Aqua: Actidose®-Aqua, ready-to-use activated charcoal suspension, contains 15 gm, 25 gm or 50 gm of activated charcoal in an aqueous suspension with a unique preservative system. Each milliliter contains 208 mg (0.208 gm) of activated charcoal.



Warnings


If patient has been given ipecac syrup, DO NOT give Actidose® WITH SORBITOL or Actidose®-AQUA until after last vomiting episode. Do not use in persons who are not fully conscious. Do not use this product unless directed by a health professional, if turpentine, corrosives, such as alkalies (lye) and strong acids, or petroleum distillates, such as kerosene, gasoline, paint thinner, cleaning fluid or furniture polish, have been ingested. This product is not recommended for use in children weighing less than 32 kg, or during multiple dose activated charcoal therapy since excessive catharsis and significant fluid and electrolyte abnormalities may occur.


Keep this and all drugs out of the reach of children.


Do not use Actidose® with Sorbitol or Actidose®-Aqua in any person known to have a rare autosomal recessive genetic intolerance to fructose. Do not use Actidose® with Sorbitol in patients who are dehydrated. Actidose® with Sorbitol may cause excessive diarrhea.



Actidose - Clinical Pharmacology



Activated Charcoal:


Activated charcoal is produced by pyrolysis of organic material, such as wood, and an activation process which cleanses and fragments the charcoal by exposure to an oxidizing gas compound of steam, oxygen, and acids at high temperatures resulting in increased surface area through the creation of numerous external and internal pores. These pores serve as reservoirs to adsorb substances admixed with activated charcoal, making it a useful adsorbent for specified toxins.


Activated charcoal is pharmacologically inert and is not absorbed in the gastrointestinal tract. Activated charcoal will adsorb a variety of organic and inorganic substances, but is especially effective in adsorbing compounds within a molecular weight range of 100 to 1,000 Daltons (AMU's).1Several other physiologic and physicochemical factors influence the adsorptive capacity of activated charcoal including: pH, charcoal:drug ratio, gastric contents, and adsorption kinetics.2


Much of the published scientific literature which studied the adsorptive capacity of activated charcoal was conducted using in vitro models. A considerable amount of the research may be invalid since the effects of physiologic pH were not taken into consideration or held constant. Using research models which simulate the gastric environment, some toxins were not adsorbed by activated charcoal. This data was inappropriately extended to imply that activated charcoal did not adsorb a toxin and therefore had no efficacy in the management of that type of poisoning incident. However, the research failed to consider that the increased pH of the small intestine provides a receptive environment for the adsorption of the toxin by activated charcoal. Activated charcoal will effectively adsorb acidic, alkaline and neutral substances (not to suggest use of activated charcoal in poisonings caused by corrosive agents2). The extent of adsorption will be dependent upon the relative solubility of the drug at a specified pH.


The optimal dosage ratio of activated charcoal to toxin is described as 10:1.3,4,17,18 Numerous factors contribute to and interfere with adsorptive capacity, therefore, the 10:1 ratio may not be valid in the clinical setting. Furthermore, a primary application of activated charcoal is in adult patients who have intentionally ingested a toxin for drug abuse or suicidal purposes. These patients may not freely provide information about the substance or amount ingested, or have a decreased level of consciousness. Under these conditions it is difficult to determine the ingestion history, making it impractical to use the 10:1 ratio. The 10:1 ratio is also impractical when large amounts of toxin have been ingested (i.e., an overdose of 50 gm of aspirin would then require 500 gm [1.1 lbs.] of activated charcoal).


Gastric contents may also compete with ingested toxins and compromise the adsorption of the toxins by activated charcoal.2 If activated charcoal is to be administered to a patient known to have ingested a large meal in close proximity to the time of treatment, a larger dose of activated charcoal may be appropriate.


Under appropriate physiologic conditions activated charcoal adsorbs toxins instantaneously. This adsorptive process is reversible and an equilibrium between free and bound toxin will exist. According to the law of mass action the amount of free drug decreases as the dose of activated charcoal increases. Therefore, large doses of activated charcoal can favor the equilibrium toward greater toxin adsorption and efficacy. There is limited evidence that desorption of a toxin from activated charcoal may occur.19 Therefore, there is a potential for toxin readsorption and enhanced toxicity. The current standard of care is to administer a cathartic with single doses of activated charcoal to hasten the elimination of the toxin/activated charcoal complex from the gastrointestinal tract.5 Cathartics should be used with extreme care during multiple dose activated charcoal therapy and it is not recommended to use a cathartic with each dose of activated charcoal.5



Sorbitol:


Sorbitol is a hexahydric sugar alcohol which primarily serves as an osmotic cathartic in Actidose® with Sorbitol.6 A secondary advantage of using sorbitol is as a palatability enhancer to decrease the innate gritty texture of activated charcoal and to provide a sweet vehicle to increase patient compliance. Sorbitol is poorly absorbed during its transit through the gastrointestinal tract. Absorbed sorbitol is metabolized by the liver and slowly converted to fructose. Insulin is not necessary for intracellular transport of sorbitol, therefore customary cathartic doses can be safely used by patients with diabetes mellitus.


As a hyperosmotic cathartic sorbitol produces a hygroscopic action resulting in increased water in the large intestine and increased intraluminal pressure which stimulates catharsis. Studies have been conducted in healthy adult human volunteers using therapeutic amounts of activated charcoal and sorbitol.8,9 Catharsis of activated charcoal occurred in an average of 1.0 - 1.5 hours and persisted for 8 - 12 hours. Fourteen poisoned patients are reported in one series representing a wide range of toxins and dosages of sorbitol resulting in the onset of catharsis in an average of 7.7 hours.10 The onset of action may be expected to be longer in patients who have ingested toxins which decrease bowel motility, such as pharmacological agents and plants with anticholinergic properties, and drugs like narcotics.20


Sorbitol does not compromise the adsorptive capacity of activated charcoal.11,12



Indications and Usage for Actidose


Actidose® with Sorbitol and Actidose®-Aqua should be used in a supervised medical facility or under the direction of a physician or poison control center.


Actidose® with Sorbitol and Actidose®-Aqua are indicated in the management of many types of poisoning emergencies when a toxin has been ingested or when indicated for a limited number of systemic poisonings resulting from parenteral overdosage or when the toxin has been totally absorbed. If physiologic conditions are optimal, activated charcoal most effectively adsorbs toxins with a molecular weight of 100 - 1,000 Daltons (AMU's).1 Activated charcoal may not be as effective in adsorbing low molecular weight substances such as aliphatic alcohols (methanol, isopropanol, ethanol, etc.) metals (iron, lead, mercury, etc.) and elements such as lithium.2 Two animal studies have demonstrated that very toxic and low molecular weight cyanide compounds are adsorbed by activated charcoal.21,22 The use of activated charcoal in toxic emergencies involving these substances is not contraindicated. Many poisonings involve multiple substances, therefore, Actidose® with Sorbitol and Actidose®-Aqua may be effective in adsorbing some or all of the ingested toxins.


Adsorption of a toxin by activated charcoal can occur anywhere in the gastrointestinal tract. However, to use Actidose® with Sorbitol or Actidose®-Aqua most effectively it is important to administer it as soon as possible to the victim of an ingested exposure. The longer the delay between the ingestion of the toxin and administration of activated charcoal, the less effective it will be. If syrup of ipecac is being used to produce emesis, administration of Actidose® with Sorbitol or Actidose®-Aqua is customarily delayed until 30 - 60 minutes after conclusion of emesis. In a study which used syrup of ipecac, 60 ml, activated charcoal did not interfere with the emetic effect of syrup of ipecac.23


If gastric lavage is being used to facilitate stomach evacuation a single dose of activated charcoal can be administered in the early stages of gastric lavage. If this technique is utilized, Actidose®-Aqua, which does not contain sorbitol, should be used. Upon completion of gastric lavage Actidose® with Sorbitol can be instilled via the lavage tube. The only disadvantage to the use of activated charcoal in this fashion is that the gastric lavage returns will be black, thus making it difficult to evaluate what the patient ingested by visual examination. The primary advantage of this therapy is that activated charcoal can be administered early to the patient. The convenient packaging of Actidose® with Sorbitol and Actidose®-Aqua (except the 15 gm/72 ml size) in a squeeze bottle with a tapered nozzle expedites emergency treatment, allowing attachment to a gastric lavage tube and administration of contents.


The most common application of activated charcoal is in acute toxic exposures where Actidose® with Sorbitol and Actidose®-Aqua can adsorb toxins thereby preventing their absorption. Activated charcoal can also be used in some toxic emergencies when absorption is complete or exposure was via a parenteral route. This application usually involves repetitive or multiple doses of activated charcoal.


Multiple doses of activated charcoal may be useful in adsorbing toxins which undergo enterohepatic circulation.13 Drugs which are subject to biliary secretion such as digitoxin are constantly secreted into the gastrointestinal tract and are reabsorbed resulting in prolonged toxicity. Frequent doses of activated charcoal can adsorb those toxins thereby preventing their reabsorption and enhancing toxin elimination through the gastrointestinal tract.


Multiple dose activated charcoal is also used in what is termed gastrointestinal dialysis.14 There are only a limited number of toxins which may be eliminated by this method. Clinical judgement and the toxin's pharmacokinetic parameters must be considered to determine the applicability of this treatment which is not universally applicable.24 The toxin passively diffuses along a concentration gradient between blood which is perfusing the gastrointestinal tract and the luminal fluids. The multiple doses of activated charcoal adsorb the toxin thereby preventing its reabsorption further maximizing the concentration gradient which permits diffusion of even more toxin into the gastric lumen. Compounds most effectively transferred by this mechanism are lipophilic, uncharged and not excessively bound to proteins. Phenobarbital and theophylline are examples of toxins which can be eliminated more rapidly by this method.15,16


Actidose® with Sorbitol should not be used in each dose of the multiple dose activated charcoal regimen unless it is necessary to produce catharsis. Actidose® with Sorbitol contains sorbitol which may produce excessive catharsis and resultant fluid and electrolyte problems if used at each dosing interval (see Precautions).9,25 Actidose®-Aqua should be used at dosage intervals when Actidose® with Sorbitol is not being used. CATHARTICS SHOULD BE USED CAUTIOUSLY AND ONLY INTERMITTENTLY DURING MULTIPLE DOSE ACTIVATED CHARCOAL THERAPY.


If catharsis of activated charcoal does not occur following the use of Actidose® with Sorbitol within 4 - 8 hours, an additional sorbitol dose of 1.5 gm/kg may be administered. Or, if desired, a saline cathartic such as magnesium citrate may be used if the patient's renal function is not impaired.


Actidose® with Sorbitol and Actidose®-Aqua are formulated in palatable vehicles which eliminate the need to add additional taste or consistency enhancers.The use of supplementary chemicals, syrups, or dairy products should be avoided since their addition may compromise the adsorptive capacity of Actidose® with Sorbitol and Actidose®-Aqua.



Contraindications


There are no known absolute contraindications to the use of activated charcoal, however, it is not an equally effective adsorbent for all toxins. It should be used with caution, if at all, in patients who have ingested corrosive agents since the activated charcoal may obscure endoscopic visualization of esophageal and gastric lesions produced by the corrosive. The use of a cathartic with activated charcoal may not be advised if a patient has significant fluid or electrolyte abnormalities. Actidose® with Sorbitol should not be used in infants due to the possibility of excessive catharsis. Young children should not receive cathartic doses of sorbitol unless hospitalized and under the immediate care of a physician.



USAGE IN CHILDREN


Actidose® with Sorbitol is not recommended in children less than one year of age.



USAGE DURING PREGNANCY OR LACTATION


Safe use during pregnancy and lactation has not been established. Actidose® with Sorbitol and Actidose®-Aqua should be used during pregnancy or lactation only if the potential benefit justifies the potential risk. No teratogenic effects have been noted in rabbits or rats.



Precautions


Actidose® with Sorbitol and Actidose®-Aqua should be used in a supervised medical facility or under the direction of a physician or poison control center.


Actidose® with Sorbitol and Actidose®-Aqua are adjuncts in the management of poisoning emergencies. Prior to the use of activated charcoal, proper basic life support measures must be implemented as well as the appropriate gastric emptying technique if indicated.


When Actidose® with Sorbitol or Actidose®-Aqua are used to treat a poisoning emergency, the patient and health care providers should be aware that activated charcoal will produce black stools. These stools may be diarrhetic and may persist for several hours.


Actidose® with Sorbitol may produce a profound cathartic effect and proper attention should be given to the patient's fluid and electrolyte needs. Actidose® with Sorbitol should be used cautiously in patients receiving multiple dose activated charcoal. If Actidose® with Sorbitol is used at each dosage interval, profound catharsis may develop which could result in dehydration, hypotension and significant electrolyte and fluid abnormalities.


A study conducted in healthy adult human volunteers who ingested therapeutic amounts of activated charcoal and sorbitol resulted in severe prolonged diarrhea, but no significant changes were noted in serum electrolytes or osmolality, BUN, or the metabolic profile as compared to the control.8


Gastrointestinal obstruction from activated charcoal may occur as a consequence of toxin-induced antiperistaltic effects. Actidose® with Sorbitol and Actidose®-Aqua should be used cautiously in patients who have been exposed to toxins which interfere with gastrointestinal tract peristalsis (i.e., anticholinergics, opioids, etc.). Bowel sounds should be frequently monitored to assess peristaltic action, especially in patients undergoing multiple dose activated charcoal therapy.



Adverse Reactions


Activated charcoal with sorbitol has produced severe hypernatremic dehydration when used in excessive amounts in pediatric patients.25,27


Aspiration of activated charcoal has been reported to produce airway obstruction and a limited number of fatalities have occurred.28,29,30,31 Bronchiolitis obliterans resulting in death has developed several weeks after the aspiration of activated charcoal.32


Gastrointestinal obstruction associated with the use of multiple dose activated charcoal therapy has been reported.33 An overdose of carbamazepine was responsible for the antiperistaltic effects which led to bowel obstruction.



Actidose Dosage and Administration


Prior to administration of Actidose® with Sorbitol or Actidose®-Aqua, shake the container thoroughly for a minimum of 30 seconds. After administration of either Actidose® with Sorbitol or Actidose®-Aqua, the container should be thoroughly rinsed with water and any residue should be administered to the patient to ensure that the entire dose has been delivered.




























Single Dose - Actidose®-Aqua
Under one year of age:1 gm/kg (5 ml/kg)
1 - 12 years of age:25-50 gm (120-240 ml)
Adults (over 12 yrs. of age):50-100 gm (240-480 ml)
Single Dose - Actidose® with Sorbitol
Under one year of age:DO NOT USE Actidose®WITH SORBITOL IN CHILDREN LESS THAN ONE YEAR OF AGE.
1 - 12 years of age:DO NOT USE Actidose®WITH SORBITOL 25 GM/120 ML IN CHILDREN WEIGHING LESS THAN 16 KG.
  DO NOT USE Actidose®WITH SORBITOL 50 GM/240 ML IN CHILDREN WEIGHING LESS THAN 32 KG
Adults (over 12 yrs.):50 gm [96 gm sorbitol]

(240 ml)
Multiple Dose - Actidose®-Aqua
Under one year of age:1 gm/kg (5 ml/kg)

q 4-6H (every 4-6 hrs)
1 - 12 years of age:25-50 gm (120-240 ml)

q 4-6H (every 4-6 hrs)
Adults (over 12 yrs.):50-100 gm (240-480 ml)

q 4-6H (every 4-6 hrs)
Multiple Dose - Actidose® with Sorbitol
  Actidose® WITH SORBITOL IS NOT RECOMMENDED FOR CHILDREN OR ADULTS IN MULTIPLE DOSE ACTIVATED CHARCOAL THERAPY DUE TO EXCESSIVE CATHARTIC ACTION.

How is Actidose Supplied






































Actidose®-AquaBottles  
  25 Gram/120 mlNDC 0574-0121-04
  50 Gram/240 mlNDC 0574-0121-08
Actidose® with Sorbitol25 Gram/120 mlNDC 0574-0120-04
  50 Gram/240 mlNDC 0574-0120-08
      
Actidose®-AquaTubes  
  15 Gram/72 mlNDC 0574-0121-25
  25 Gram/120 mlNDC 0574-0121-74
  50 Gram/240 mlNDC 0574-0121-76
Actidose® with Sorbitol25 Gram/120 mlNDC 0574-0120-74
  50 Gram/240 mlNDC 0574-0120-76

REFERENCES


  1. Activated Charcoal, Antidotal and Other Medicinal Uses, Marcel Dekker, New York, 1980.

  2. Clinical Pharmacokinetics. 1982; 7: 465-489.

  3. Handbook of Common Poisonings in Children, American Academy of Pediatrics, Evanston, 1983.

  4. Am J Emerg Med. 1985; 3: 280-283.

  5. Poisindex Information System, Micromedix, Denver, 1991.

  6. J Pediatrics. 1981; 98: 157-158.

  7. Diabetes Care. 1978; 1: 223-230.

  8. Clinical Toxicology. 1985; 22: 529-536.

  9. Ann. Emerg. Med. 1985; 14: 1152-1155.

  10. Clinical Toxicology. 1985; 23: 579-587.

  11. J. Pharmacol. Exp. Ther. 1982; 221: 656-663.

  12. Am. J. Hosp. Pharm. 1978, 35: 1355-1359.

  13. Lancet. 1981; 2: 1177-1178.

  14. NEJM. 1982; 307: 676-678.

  15. NEJM. 1982; 307: 642-644.

  16. Clin. Pharmacol. Therap. 1983; 34: 663-666.

  17. Medical Toxicology. New York, Elsevier, 1988.

  18. Clinical Management of Poisoning and Drug Overdose. Philadelphia, W.B. Saunders Co., 1990.

  19. Arch Intern Med. 1987; 147: 1390-1392.

  20. Clin Toxicol. 1989; 27: 91-99.

  21. Ann Emerg Med. 1988; 17: 595-598.

  22. Ann Emerg Med. 1990; 19: 453.

  23. Ann Emerg Med. 1987; 16: 164-166.

  24. Ann Emerg Med. 1991; 20: 529-531.

  25. J. Pediatrics. 1986; 109: 719-722.

  26. Ann Emerg Med. 1986; 15: 1214-1218.

  27. J. Pediatrics. 1988; 112: 333.

  28. Vet Hum Toxicol. 1989; 31: 335.

  29. B Med J. 1988; 297: 459-460.

  30. NCMJ. 1990; 51: 79-80.

  31. Ann Emerg Med. 1981; 10: 528-529.

  32. Chest. 1989; 96: 672-674.

  33. J Emerg Med. 1986; 4: 401-407.


Paddock Laboratories, Inc.

Minneapolis, MN 55427

(06-08)



PRINCIPAL DISPLAY PANEL - 120 mL Bottle


NDC 0574-0120-04

Actidose®

with Sorbitol

ACTIVATED CHARCOAL SUSPENSION

25 grams Activated Charcoal

48 grams Sorbitol

POISON ADSORBENT


If possible call a Poison Control Center,

emergency medical facility, or health

professional for help before using this

product. If help cannot be reached quickly,

follow directions under this label. Read label

warnings and directions upon buying this

product.Write emergency phone numbers

in space provided.


Emergency

Phone No.:


NET CONTENTS: 120 mL (4 fl oz)




PRINCIPAL DISPLAY PANEL - 240 mL Bottle


NDC 0574-0120-08

Actidose®

with Sorbitol

ACTIVATED CHARCOAL SUSPENSION

50 grams Activated Charcoal

96 grams Sorbitol

POISON ADSORBENT


If possible call a Poison Control Center,

emergency medical facility, or health

professional for help before using this

product. If help cannot be reached quickly,

follow directions under this label. Read label

warnings and directions upon buying this

product.Write emergency phone numbers

in space provided.


Emergency

Phone No.:


NET CONTENTS: 240 mL (8 fl oz)




PRINCIPAL DISPLAY PANEL - 120 mL Tube


Paddock

Laboratories, Inc.


Actidose

with Sorbitol™

ACTIVATED CHARCOAL SUSPENSION


25 grams Activated Charcoal

48 grams Sorbitol




PRINCIPAL DISPLAY PANEL - 240 mL Tube


Paddock

Laboratories, Inc.


Actidose

with Sorbitol™

ACTIVATED CHARCOAL SUSPENSION


50 grams Activated Charcoal

96 grams Sorbitol










Actidose 
activated charcoal  suspension










Product Information
Product TypeHUMAN PRESCRIPTION DRUGNDC Product Code (Source)0574-0120
Route of AdministrationORALDEA Schedule    








Active Ingredient/Active Moiety
Ingredient NameBasis of StrengthStrength
Activated Charcoal (Activated Charcoal)Activated Charcoal208 mg  in 1 mL












Inactive Ingredients
Ingredient NameStrength
Sorbitol400 mg  in 1 mL
Water 
propylene glycol 
glycerin 


















Product Characteristics
Color    Score    
ShapeSize
FlavorImprint Code
Contains      






















Packaging
#NDCPackage DescriptionMultilevel Packaging
10574-0120-04120 mL In 1 BOTTLENone
20574-0120-08240 mL In 1 BOTTLENone
30574-0120-74120 mL In 1 TUBENone
40574-0120-76240 mL In 1 TUBENone










Marketing Information
Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
Unapproved other10/01/1983


Labeler - Paddock Laboratories, Inc. (086116803)









Establishment
NameAddressID/FEIOperations
Paddock Laboratories, Inc.086116803MANUFACTURE
Revised: 06/2009Paddock Laboratories, Inc.

More Actidose resources


  • Actidose Side Effects (in more detail)
  • Actidose Use in Pregnancy & Breastfeeding
  • Actidose Drug Interactions
  • Actidose Support Group
  • 0 Reviews for Actidose - Add your own review/rating


Compare Actidose with other medications


  • Gas
  • Gastrointestinal Decontamination

Tuesday, 31 July 2012

Penbritin Syrup 125mg / 5ml





1. Name Of The Medicinal Product



Penbritin Syrup (125 mg/5 ml)


2. Qualitative And Quantitative Composition



When reconstituted each 5 ml contains 125 mg ampicillin as Ampicillin Trihydrate.



3. Pharmaceutical Form



Powder for oral suspension.



4. Clinical Particulars



4.1 Therapeutic Indications



Ampicillin is a broad-spectrum penicillin, indicated for the treatment of a wide range of bacterial infections caused by ampicillin-sensitive organisms. Typical indications include: ear, nose and throat infections, bronchitis, pneumonia, urinary tract infections, gonorrhoea, gynaecological infections, septicaemia, peritonitis, endocarditis, meningitis, enteric fever, gastro-intestinal infections.



Parenteral usage is indicated where oral dosage is inappropriate.



4.2 Posology And Method Of Administration




























































Usual adult dosage (including elderly patients):



 


   


Ear, nose and throat infections:




250mg four times a day.


  


Bronchitis:




Routine therapy:




250mg four times a day.


 


High-dosage therapy:




1 g four times a day.


  


Pneumonia:




 



 




500 mg four times a day.


 


Urinary tract infections:




500 mg three times a day.


  


Gonorrhoea:




2 g orally with 1 g probenecid as a single dose.


  


Repeated doses are recommended for the treatment of females.


   


Gastro-intestinal infections:




500-750 mg three to four times daily.


  


Enteric:




Acute:




1-2 g four times a day for two weeks.


 


Carriers:




1-2 g four times a day for four to twelve weeks.



 


  


Usual children's dosage (under 10 years):


   


Half adult routine dosage.


   

 

 

 

 


All recommended dosages are a guide only. In severe infections the above dosages may be increased, or ampicillin given by injection. Oral doses of ampicillin should be taken half to one hour before meals.



Renal Impairment:



In the presence of severe renal impairment (creatinine clearance <10ml/min) a reduction in dose or extension of dose interval should be considered. In cases of dialysis, an additional normal dose should be administered after the procedure.



Administration:



Oral



4.3 Contraindications



Ampicillin is a penicillin and should not be given to patients with a history of hypersensitivity to beta-lactam antibiotics (e.g. ampicillin, penicillins, cephalosporins) or excipients.



4.4 Special Warnings And Precautions For Use



Before initiating therapy with ampicillin, careful enquiry should be made concerning previous hypersensitivity reactions to beta-lactam antibiotics.



Serious and occasionally fatal hypersensitivity reactions (anaphylaxis) have been reported in patients receiving beta-lactam antibiotics. Although anaphylaxis is more frequent following parenteral therapy, it has occurred in patients on oral penicillins. These reactions are more likely to occur in individuals with a history of beta-lactam hypersensitivity.



Ampicillin should be avoided if infectious mononucleosis and/or acute or chronic leukaemia of lymphoid origin are suspected. The occurrence of a skin rash has been associated with these conditions following the administration of ampicillin.



Prolonged use may occasionally result in overgrowth of non-susceptible organisms.



Dosage should be adjusted in patients with renal impairment (see section 4.2).



Contains sodium benzoate.



Sodium content: Each 5 ml contains 16.7 mg of sodium. This sodium content should be included in the daily allowance of patients on sodium restricted diets.



Sucrose: Each 5 ml contains approximately 3.6g of sucrose.



4.5 Interaction With Other Medicinal Products And Other Forms Of Interaction



Bacteriostatic drugs may interfere with the bactericidal action of ampicillin.



In common with other oral broad-spectrum antibiotics, ampicillin may reduce the efficacy of oral contraceptives and patients should be warned accordingly.



Probenecid decreases the renal tubular secretion of ampicillin. Concurrent use with ampicillin may result in increased and prolonged blood levels of ampicillin.



Concurrent administration of allopurinol during treatment with ampicillin can increase the likelihood of allergic skin reactions.



It is recommended that when testing for the presence of glucose in urine during ampicillin treatment, enzymatic glucose oxidase methods should be used. Due to the high urinary concentrations of ampicillin, false positive readings are common with chemical methods.



4.6 Pregnancy And Lactation



Pregnancy: Animal studies with ampicillin have shown no teratogenic effects. The product has been in extensive clinical use since 1961 and its use in human pregnancy has been well documented in clinical studies. When antibiotic therapy is required during pregnancy, ampicillin may be considered appropriate.



Lactation: During lactation, trace quantities of penicillins can be detected in breast milk. Adequate human and animal data on use of ampicillin during lactation are not available.



4.7 Effects On Ability To Drive And Use Machines



Adverse effects on the ability to drive or operate machinery have not been observed.



4.8 Undesirable Effects



Hypersensitivity reactions: If any hypersensitivity reaction occurs, the treatment should be discontinued.



Skin rash, pruritus and urticaria have been reported occasionally. The incidence is higher in patients suffering from infectious mononucleosis and acute or chronic leukaemia of lymphoid origin. Purpura has also been reported. Rarely, skin reactions such as erythema multiforme and Stevens-Johnson syndrome, and toxic epidermal necrolysis have been reported.



As with other antibiotics, anaphylaxis (see Item 4.4 – Warnings) has been reported rarely.



Renal effects: Interstitial nephritis can occur rarely.



Gastrointestinal reactions: Effects include nausea, vomiting and diarrhoea. Pseudomembraneous colitis and haemorrhagic colitis has been reported rarely.



Hepatic effects: As with other beta-lactam antibiotics, hepatitis and cholestatic jaundice have been reported rarely. As with most other antibiotics, a moderate and transient increase in transaminases has been reported.



Haematological effects: As with other beta-lactams, haematological effects including transient leucopenia, transient thrombocytopenia and haemolytic anaemia have been reported rarely.



Prolongation of bleeding time and prothrombin have also been reported rarely.



4.9 Overdose



Gastrointestinal effects such as nausea, vomiting and diarrhoea may be evident and should be treated symptomatically.



Ampicillin may be removed from the circulation by haemodialysis.



5. Pharmacological Properties



5.1 Pharmacodynamic Properties



Ampicillin trihydrate is an oral antibiotic, active against a wide range of Gram-negative and Gram-positive organisms.



5.2 Pharmacokinetic Properties



Absorption: The oral administration of 250 mg and 500 mg of ampicillin on a fasting stomach produces maximum serum levels of ± 2 and ± 4 mcg per ml, respectively, after 2 hours. Bioavailability is 30 to 40%. The absorption of orally administered ampicillin can be diminished by food.



Distribution: Serum protein binding ampicillin is about 20 %. Plasma half-life is between 1 and 1½ hours.



Ampicillin diffuses into most tissues and body fluids. Its presence in therapeutic concentrations has been detected in, among others, bronchial secretions sinuses, saliva, CSF (variable percentage depending on the degree of meningeal inflammation), bile, serous membranes and middle ear.



Crosses the meningeal barrier: There is little ampicillin diffusion into the cerebrospinal fluid, except in cases of inflamed meninges, in which it can reach therapeutic concentrations when administered in high doses and especially by the intravenous route.



Cross the placenta: Ampicillin diffuses through the placenta.



Passes into mother's milk: Ampicillin is detected in small quantities in mothers' milk.



Metabolism and Excretion: Ampicillin is eliminated chiefly through the urine. Approximately 30% of the dose administered orally and over 60 % of the dose administered parenterally are eliminated in active form in the urine during the 24 hours which follow the administration of ampicillin. Urinary concentrations are higher following parenteral administration.



A small percentage is eliminated in the bile where high concentrations are found. Excretion may be delayed in cases of renal failure in accordance with its severity.



5.3 Preclinical Safety Data



Not relevant.



6. Pharmaceutical Particulars



6.1 List Of Excipients



Sodium Benzoate



Sodium Chloride



Apricot Dry Flavour



Caramel Dry Flavour



Peppermint Extra Dry Flavour



Methyl Polysiloxane



Sodium Citrate Anhydrous



Sucrose



6.2 Incompatibilities



None known



6.3 Shelf Life



Powder: 3 years



Once dispensed, the products remain stable for 14 days when stored at 2-8oC in a refrigerator.



6.4 Special Precautions For Storage



Do not store above 25oC.



Once dispensed, store at 2-8oC in a refrigerator (14 days).



6.5 Nature And Contents Of Container



White flint glass bottle fitted with aluminium roll-on-pilfer-proof (ROPP) cap.



Powder for reconstitution to 100ml.



6.6 Special Precautions For Disposal And Other Handling



If dilution of the reconstitution syrup is required, Syrup BP should be used.



7. Marketing Authorisation Holder



Chemidex Pharma Limited



Chemidex House



Egham Business Village,



Crabtree Road, Egham, Surrey



TW20 8RB



United Kingdom



8. Marketing Authorisation Number(S)



PL 17736/0073



9. Date Of First Authorisation/Renewal Of The Authorisation



25th February 2005



10. Date Of Revision Of The Text



09/10/2007